TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37832571

Group type: EXPERIMENTAL
Intervention: Experimental regimens composed of different combinations of rifampicin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), moxifloxacin (M), and SQ109 (Q).
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard-of-care treatment regimen.
Number of subjects: 397
Study: 37832606

Group type: EXPERIMENTAL
Intervention: Balloon-expandable (BE) valve
Number of subjects: 396

Group type: COMPARATOR
Intervention: Self-expanding (SE) valve
Number of subjects: 396
Study: 37832758

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg once daily for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37832982

Group type: EXPERIMENTAL
Intervention: GPi-DBS
Number of subjects: 98

Group type: COMPARATOR
Intervention: STN-DBS
Number of subjects: 98
Study: 37832989

Group type: EXPERIMENTAL
Intervention: ECO threshold of 6 ppm
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ECO threshold of 7 ppm
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ECO threshold of 8 ppm
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: ECO threshold of 9 ppm
Number of subjects: 766
Study: 37833046

Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (SCS)
Number of subjects: 9
Study: 37833194

Group type: EXPERIMENTAL
Intervention: High PEEP (12 cmH2O) with recruitment manoeuvres (RM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low PEEP (3.7 cmH2O)
Number of subjects: 48
Study: 37833387

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) patients
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 93
Study: 37833472

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg given six hours after interscalene block
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo given six hours after interscalene block
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Hydromorphone 2 mg and Placebo
Number of subjects: 73
Study: 37833493

Group type: EXPERIMENTAL
Intervention: HSK21542 (2 μg/0.212 μCi/kg)
Number of subjects: 0
Study: 37833567

Group type: COMPARATOR
Intervention: Summer (SPA 7.2 ± 2.9, p = 0.0002)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Spring (SPA 7.5 ± 2.9, p = 0.025)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Fall (SPA 7.6 ± 3, p = 0.038)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Summer (Energy cost of SPA 2.18 ± 0.83, p = 0.0008)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Spring (Energy cost of SPA 2.186 ± 0.83, p = 0.017)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Fall (Energy cost of SPA 2.146 ± 0.75, p = 0.038)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Summer (Protein oxidation rates 292 ± 117 kcal/day, β = -21.2, p = 0.08)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Carbohydrate and lipid oxidation rates (kcal/day)
Number of subjects: 671

Group type: COMPARATOR
Intervention: RER and 24-h EE
Number of subjects: 671
Study: 37833640

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (hospitalized patients with respiratory infections other than COVID-19)
Number of subjects: 0
Study: 37833645

Group type: EXPERIMENTAL
Intervention: Balance telerehabilitation (experimental group, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unsupervised exercises (control group, n=40)
Number of subjects: 80
Study: 37833651

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study: 37833679

Group type: EXPERIMENTAL
Intervention: Liberalized potassium diet (3500 mg dietary K daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard potassium restricted diet (<2000 mg dietary K daily)
Number of subjects: 30
Study: 37833681

Group type: EXPERIMENTAL
Intervention: Classic RTT
Number of subjects: 925

Group type: COMPARATOR
Intervention: Comparison across disorders
Number of subjects: 925
Study: 37833732

Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Number of subjects: 12
Study: 37833737

Group type: EXPERIMENTAL
Intervention: Shared decision making assessed using the CollaboRATE survey
Number of subjects: 305
Study: 37833799

Group type: EXPERIMENTAL
Intervention: Low HDL-C, low apolipoprotein A-1, high triglyceride (TG), high apolipoprotein B (ApoB)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: High LDL-C
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: PDW
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Plateletcrit
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Bleeding scores
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: LDL-C and homocysteine
Number of subjects: 457
Study: 37834761

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 37834963

Group type: EXPERIMENTAL
Intervention: Symptomatic heart failure (ACC/AHA Stage C) at enrolment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: HF stages A, B, and C
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: NYHA functional classification
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Clinical events including mortality, HF hospitalizations, and HF-related healthcare resource utilization
Number of subjects: 300
Study: 37835071

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) combined with B-cell depletion therapy
Number of subjects: 10
Study: 37835090

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Intervention (TLI) adapted from the National Diabetes Prevention Program (DPP) for individuals with chronic SCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral support for caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition for caregivers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lock-step circuit resistance training, calorie-restricted Mediterranean-style diet, and 16 educational sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver program
Number of subjects: 0
Study: 37835830

Group type: EXPERIMENTAL
Intervention: Morton's extension
Number of subjects: 25
Study: 37837240

Group type: EXPERIMENTAL
Intervention: Contact X-ray brachytherapy (CXB) boost
Number of subjects: 141

Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) boost
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) surgery
Number of subjects: 141
Study: 37837353

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 201
Study: 37837376

Group type: EXPERIMENTAL
Intervention: Immunotherapy regimen during ATI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clinical trial staff interactions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Trial experiences
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Considerations for future trials
Number of subjects: 14
Study: 37837462

Group type: EXPERIMENTAL
Intervention: TICK-B
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 37837493

Group type: EXPERIMENTAL
Intervention: Avène thermal spring water hydrotherapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no hydrotherapy)
Number of subjects: 26
Study: 37837629

Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA positivity
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Post-ACT ctDNA positivity
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Post-ACT ctDNA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Model with ctDNA
Number of subjects: 100
Study: 37837651

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2511

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 2511
Study: 37837720

Group type: EXPERIMENTAL
Intervention: Ongoing VAD support
Number of subjects: 393
Study: 37837942

Group type: EXPERIMENTAL
Intervention: Treatment strategies at t0 (time of active suicidal ideation with intent)
Number of subjects: 137
Study: 37837989

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with medical treatment
Number of subjects: 253

Group type: COMPARATOR
Intervention: Medical treatment alone (standard of care)
Number of subjects: 253
Study: 37838080

Group type: EXPERIMENTAL
Intervention: Surprise Question (SQ)
Number of subjects: 301
Study: 37838094

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study: 37838323

Group type: EXPERIMENTAL
Intervention: Small-bowel capsule endoscopy (SB-CE)
Number of subjects: 174
Study: 37838555

Group type: EXPERIMENTAL
Intervention: Radium-223 (Ra-223)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: High baseline bone alkaline phosphatase (BAP)
Number of subjects: 169
Study: 37838556

Group type: EXPERIMENTAL
Intervention: MRI with targeted biopsy (TBx)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Systematic transrectal ultrasound biopsy (SBx)
Number of subjects: 83
Study: 37838604

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1000 mg i.v. administered 24-72 hours before surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (administered 24-72 hours before surgery)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 37838623

Group type: EXPERIMENTAL
Intervention: SHR7280 (200 mg QD, 300 mg QD, 200 mg BID)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37838653

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: treatment as usual (control)
Number of subjects: 161
Study: 37838662

Group type: EXPERIMENTAL
Intervention: Birth companion intervention package
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 744
Study: 37838669

Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 41
Study: 37838672

Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Stress Reduction (MBSR) program as add on to usual care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 240
Study: 37838686

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) during chemotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Minnesota Manual Dexterity Test (MMDT) during chemotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Module Cancer Related Fatigue (EORTC-QLQ-FA12) during chemotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Semmes Weinstein Monofilament Test (SWMT) during chemotherapy
Number of subjects: 56
Study: 37838727

Group type: EXPERIMENTAL
Intervention: Culturally tailored virtual information and coaching/support program (TICAA) + American Cancer Society (ACS) website
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group using only ACS website
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Culturally tailored virtual information and coaching/support program (TICAA)
Number of subjects: 199
Study: 37838795

Group type: EXPERIMENTAL
Intervention: Lumped parameter model for assessing coronary blood flow (CBF) based on clinical imaging and in-vivo data during invasive coronary functional assessment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical routine tests for assessing ischemic risk in AAOCA patients.
Number of subjects: 0
Study: 37838987

Group type: EXPERIMENTAL
Intervention: Trifarotene 50 μg/g
Number of subjects: 121

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 121
Study: 37839272

Group type: EXPERIMENTAL
Intervention: Pitolisant (Saturday and Sunday)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Modafinil (Monday to Friday)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pitolisant-supported bridging
Number of subjects: 41
Study: 37839313

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Paclitaxel+sapanisertib
Number of subjects: 234
Study: 37839434

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 412

Group type: COMPARATOR
Intervention: Avoiding oral anticoagulation (control)
Number of subjects: 412
Study: 37839506

Group type: EXPERIMENTAL
Intervention: Structured model of care including 3-hour patient education and 8-12 weeks individually tailored exercise programs
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Structured model of care
Number of subjects: 393

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 393
Study: 37839546

Group type: COMPARATOR
Intervention: Mediterranean diet intervention
Number of subjects: 692

Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction program
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 692
Study: 37839573

Group type: EXPERIMENTAL
Intervention: High plasma fibrinogen (FIB) level
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: High admission pulse rate
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Plasma FIB level
Number of subjects: 587
Study: 37839707

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/d)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 37839894

Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, cyclophosphamide, and thalidomide (CPCT) regimen
Number of subjects: 45
Study: 37839923

Group type: EXPERIMENTAL
Intervention: New-onset diabetes in participants without diabetes at enrollment
Number of subjects: 98
Study: 37839958

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) - 10 weekly sessions of 120 minutes each
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 37840055

Group type: EXPERIMENTAL
Intervention: MY-RADS protocol for WB-MRI
Number of subjects: 121
Study: 37840095

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37840107

Group type: EXPERIMENTAL
Intervention: Cutaneous HPV types 27, 57, and 2
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Persistent warts
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Viral load quantification
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 269
Study: 37840119

Group type: EXPERIMENTAL
Intervention: Spesolimab (900 mg, single intravenous dose on day 1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spesolimab
Number of subjects: 11
Study: 37840134

Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg (SAR200 + 26W)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg (SAR150 + 26W)
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo with 52-week GC taper (PBO + 52W)
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo with 26-week GC taper (PBO + 26W)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 83
Study: 37840155

Group type: EXPERIMENTAL
Intervention: Danuglipron (20 mg)
Number of subjects: 39
Study: 37840504

Group type: EXPERIMENTAL
Intervention: Autonomous music-based digital walking intervention (30-minute sessions, 5 times a week for 4 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Autonomous music-based digital walking intervention
Number of subjects: 23
Study: 37840530

Group type: EXPERIMENTAL
Intervention: Abemaciclib monotherapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus LY3023414
Number of subjects: 106

Group type: COMPARATOR
Intervention: SOC chemotherapy (gemcitabine or capecitabine)
Number of subjects: 106
Study: 37840634

Group type: EXPERIMENTAL
Intervention: HASBLED
Number of subjects: 7613

Group type: EXPERIMENTAL
Intervention: ATRIA
Number of subjects: 7613

Group type: EXPERIMENTAL
Intervention: ORBIT
Number of subjects: 7613

Group type: EXPERIMENTAL
Intervention: Major bleeding (MB)
Number of subjects: 7613

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 7613
Study: 37840766

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied to lesions once or twice daily for 52 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vehicle control (not explicitly detailed in the abstract)
Number of subjects: 57
Study: 37840952

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients
Number of subjects: 199433

Group type: COMPARATOR
Intervention: Age-and sex matched controls
Number of subjects: 199433
Study: 37841423

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 961
Study: 37841441

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intraperitoneal and systemic (NIPS) albumin-bound paclitaxel combined with Camrelizumab and S-1
Number of subjects: 0
Study: 37841647

Group type: EXPERIMENTAL
Intervention: Holistic digital intervention including personalized recommendations for diet, physical activity, sleep, and stress management.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 56
Study: 37841869

Group type: EXPERIMENTAL
Intervention: Caring Contact letters sent by CareSource
Number of subjects: 43000

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 43000
Study: 37841873

Group type: EXPERIMENTAL
Intervention: Click-decoding using a chronically implanted high density electrocorticographic (ECoG) BCI
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: New click decoder trained with < 15 min of data
Number of subjects: 1
Study: 37841877

Group type: EXPERIMENTAL
Intervention: Brain-based graph-theoretical predictive model (GPM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brain-based graph-theoretical predictive model (GPM) derived from individuals with unipolar disorders
Number of subjects: 80
Study: 37842200

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) combined with fruquintinib and tislelizumab
Number of subjects: 68
Study: 37842323

Group type: EXPERIMENTAL
Intervention: shen-based qigong exercise intervention along with daily rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: daily rehabilitation
Number of subjects: 60
Study: 37842322

Group type: EXPERIMENTAL
Intervention: Deimplementation strategy
Number of subjects: 0
Study: 37842523

Group type: EXPERIMENTAL
Intervention: Ultrasonic shears
Number of subjects: 40

Group type: COMPARATOR
Intervention: Advanced bipolar device
Number of subjects: 40
Study: 37842826

Group type: EXPERIMENTAL
Intervention: Immunomodulatory interventions
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 37843101

Group type: EXPERIMENTAL
Intervention: Annual screening for ovarian cancer (over 670,000 yearly screens from 2001-2011)
Number of subjects: 202000

Group type: EXPERIMENTAL
Intervention: Comprehensive electronic trial management system
Number of subjects: 202000

Group type: EXPERIMENTAL
Intervention: Automation of eligibility checks and appointment scheduling
Number of subjects: 202000
Study: 37843478

Group type: EXPERIMENTAL
Intervention: Instability
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Trauma
Number of subjects: 360
Study: 37843629

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal for at least 48 hours
Number of subjects: 412

Group type: COMPARATOR
Intervention: Ventilation alone
Number of subjects: 412
Study: 37843637

Group type: EXPERIMENTAL
Intervention: EMD application (EMD+)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Subgingival instrumentation without EMD (EMD-)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of EMD+ and EMD-
Number of subjects: 22
Study: 37843770

Group type: EXPERIMENTAL
Intervention: Simplified clinical screening model for predicting GDM risk
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Comparison with three other published models
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Bootstrapping for internal validation
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Hosmer-Lemeshow goodness-of-fit test
Number of subjects: 1289
Study: 37843771

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg, 10 mg, 15 mg
Number of subjects: 0
Study: 37843772

Group type: EXPERIMENTAL
Intervention: Micro-sized allogeneic serum eye drops (7 µl/unit)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Conventional-sized allogeneic serum eye drops (50 µl/unit)
Number of subjects: 49

Group type: COMPARATOR
Intervention: User-friendliness of conventional drop system
Number of subjects: 49
Study: 37843843

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (400 mg/d for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 37843910

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0
Study: 37844137

Group type: EXPERIMENTAL
Intervention: SAVAL self-expandable paclitaxel drug-eluting stent (DES)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) with an uncoated balloon
Number of subjects: 201
Study: 37844320

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic solution (MIEBO™; Bausch + Lomb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline eye drops
Number of subjects: 0